Clinical Trials Logo

Clinical Trial Summary

The Pure-Vu® System can be effectively used as a cleansing device in patients admitted with acute LGIB to the intensive care unit and the regular nurse floor (RNF) bypassing the need to administer an oral bowel preparation for adequate visualization and hence decreasing time to colonoscopy and improving diagnostic and therapeutic yield.


Clinical Trial Description

Acute lower gastrointestinal bleeding (LGIB), while generally defined as gastrointestinal bleeding distal to the ligament of Treitz, can be categorized into small bowel and colorectal bleeding, two sites with distinct presentations as well as diagnostic and management options (1). Acute LGIB secondary to a colorectal source usually presents with sudden onset hematochezia with or without acute blood loss anemia and hemodynamic instability, and usually leads to multiple invasive procedures and hospitalizations. It accounts for up to one-third of all hospitalizations related to GIB (2). The current guidelines recommend urgent colonoscopy to be performed within 8 to 24 hours of presentation and after adequate colon preparation to improve visualization and diagnostic/therapeutic yield (1). While studies looking at optimal timing of colonoscopy are limited for patients with acute LGIB, a study comparing 48 patients with diverticular bleeding who underwent colonoscopy after rapid polyethylene glycol (PEG) preparation and within 12 hours of presentation with endoscopic hemostasis compared to 73 controls without endoscopic hemostasis, found a significant improvement in outcomes in the group that underwent hemostasis, including bleeding (0% vs. 53%) and hospital length (median of 2 days vs. 5 days) (3). In another RCT of 100 patients presenting with LGIB, colonoscopy within 8 hours of presentation after rapid preparation lead to a more definite diagnosis compared to patients who underwent elective colonoscopy within 96 hours of presentation (4). Urgent colonoscopy however requires the rapid administration of a large volume bowel preparation over 3-4 hours until the rectal effluent is clear (1). Purge preparation can be challenging in critically ill patients and frequently requires the placement of a nasogastric tube for administration of the preparation which could place the patient at risk of aspiration, poor tolerance, and rarely, electrolyte imbalances (1). Moreover, bleeding can subside while awaiting resuscitation and bowel preparation prior to endoscopic intervention, which could lead to a decreased diagnostic and therapeutic yield. The guidelines recommend against unprepped colonoscopy due to poor visualization and increased perforation risk (1). A pilot study looked at the effect of "hydroflush colonoscopy" in acute LGIB with minimally prepped colons (tap water enema without oral preparation). "Hydroflush colonoscopy" was defined as colonoscopy using a combination of a water jet pump irrigation and a mechanical endoscope suction device (BioVac direct suction device). Out of the 12 patients included, the cecum was reached 69% of the time and endoscopic visualization was found to be adequate to find the source of bleeding in all procedures (5). The Pure-Vu® System (MotusGI Ltd.), a novel Food and Drug Administration (FDA) 510k cleared intra-procedural cleansing device, has been recently introduced. The Pure-Vu® System integrates with the colonoscope and generates a pulsed vortex mixture of water and air in order to remove debris and is active at the time of cleansing to evacuate colonic contents simultaneously (6). Its effectiveness has been studied in colonoscopies requiring minimal preparation regimens with excellent and safe results (7,8). A multicenter European feasibility study looked at 47 patients referred for colonoscopy who received a limited bowel preparation and found significant improvement in the proportion of patients with adequate preparation, with a median Boston bowel preparation score (BBPS) increased from 3[0-5] to 9 [8-9] (8). The REDUCE trial (9), another multicenter, single-arm study, was the first trial to study Pure-Vu® in the inpatient setting, which enrolled 95 hospitalized subjects. Adequate bowel preparation improved from 38% (95% CI 28,49) to 96% (CI 90-99) in the evaluated segments. The mean BBPS improved from 1.74 in the left colon, 1.74 in the transverse colon, 1.5 in the right colon to 2.89, 2.91 and 2.86 respectively (p<0.001) (9). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04729946
Study type Interventional
Source The Cleveland Clinic
Contact
Status Terminated
Phase N/A
Start date March 3, 2021
Completion date April 6, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT04600609 - Examining the Experiences of Children With Blood Disorders
Active, not recruiting NCT04309084 - Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Phase 1
Completed NCT04757285 - Copeptin and Psychological Stress of Medic During COVID-19 Pandemic
Not yet recruiting NCT06242353 - Coagulopathy in Childhood Acute Lymphoblastic Leukaemia
Completed NCT04499612 - Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
Not yet recruiting NCT06328647 - Quantra Point-of-Care Hemostasis Monitoring N/A
Not yet recruiting NCT04179357 - Hemostatic Disorders on Intensive Care Patients.
Recruiting NCT04650529 - Gyeongsang National University Hospital Registry
Completed NCT03756948 - Viscoelastic Tests-Guided Therapy In Liver Transplantation N/A
Recruiting NCT05476458 - To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
Recruiting NCT04762576 - Thrombin in Cardiac Surgery
Completed NCT03555383 - Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)
Terminated NCT03806556 - A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia Phase 1/Phase 2
Recruiting NCT03281252 - A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China N/A